Author:
Lee David,Natale Ronald B.,Nadler Eric,Jain Vinay K.
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference5 articles.
1. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration;Wedge;Cancer Res,2002
2. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors;Holden;Ann Oncol,2005
3. A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors;Minami;Proc Am Soc Clin Oncol,2003
4. A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa') in patients with NSCLC: results of a randomized, double-blind phase II study;Natale;Lung Cancer,2005
5. ZD6474 plus docetaxel in patients with previously treated NSCLC: results of a randomized, placebo-controlled phase II trial;Herbst;Lung Cancer,2005
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献